AU2021279205B2 - Methods of treating pulmonary fibrosis - Google Patents

Methods of treating pulmonary fibrosis

Info

Publication number
AU2021279205B2
AU2021279205B2 AU2021279205A AU2021279205A AU2021279205B2 AU 2021279205 B2 AU2021279205 B2 AU 2021279205B2 AU 2021279205 A AU2021279205 A AU 2021279205A AU 2021279205 A AU2021279205 A AU 2021279205A AU 2021279205 B2 AU2021279205 B2 AU 2021279205B2
Authority
AU
Australia
Prior art keywords
formula
pulmonary fibrosis
compound
fibrosis
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2021279205A
Other languages
English (en)
Other versions
AU2021279205A1 (en
Inventor
Chris Burns
Mark Graeme DEVLIN
John Lambert
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amplia Therapeutics Ltd
Original Assignee
Amplia Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2020901743A external-priority patent/AU2020901743A0/en
Application filed by Amplia Therapeutics Ltd filed Critical Amplia Therapeutics Ltd
Publication of AU2021279205A1 publication Critical patent/AU2021279205A1/en
Assigned to AMPLIA THERAPEUTICS LIMITED reassignment AMPLIA THERAPEUTICS LIMITED Request for Assignment Assignors: AMPLIA THERAPEUTICS PTY LTD
Application granted granted Critical
Publication of AU2021279205B2 publication Critical patent/AU2021279205B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2021279205A 2020-05-28 2021-05-17 Methods of treating pulmonary fibrosis Active AU2021279205B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2020901743 2020-05-28
AU2020901743A AU2020901743A0 (en) 2020-05-28 Methods of treating pulmonary fibrosis
PCT/AU2021/050457 WO2021237273A1 (en) 2020-05-28 2021-05-17 Methods of treating pulmonary fibrosis

Publications (2)

Publication Number Publication Date
AU2021279205A1 AU2021279205A1 (en) 2022-12-08
AU2021279205B2 true AU2021279205B2 (en) 2025-12-04

Family

ID=78745664

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021279205A Active AU2021279205B2 (en) 2020-05-28 2021-05-17 Methods of treating pulmonary fibrosis

Country Status (9)

Country Link
US (1) US20230190746A1 (https=)
EP (1) EP4157278A4 (https=)
JP (1) JP7745571B2 (https=)
KR (1) KR20230017843A (https=)
CN (1) CN115867281A (https=)
AU (1) AU2021279205B2 (https=)
CA (1) CA3177652A1 (https=)
NZ (1) NZ793855A (https=)
WO (1) WO2021237273A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES3001119T3 (es) 2019-03-28 2025-03-04 Amplia Therapeutics Ltd Una sal y forma cristalina de un inhibidor de FAK
WO2023139154A1 (en) * 2022-01-19 2023-07-27 Nordic Bioscience A/S A method for detecting covid-19 in a patient

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012110774A1 (en) * 2011-02-17 2012-08-23 Cancer Therapeutics Crc Pty Limited Selective fak inhibitors
WO2014027199A1 (en) * 2012-08-14 2014-02-20 Cancer Therapeutics Crc Pty Ltd Fak and flt3 inhibitors
WO2020191448A1 (en) * 2019-03-28 2020-10-01 Amplia Therapeutics Limited A salt and crystal form of a fak inhibitor

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012110774A1 (en) * 2011-02-17 2012-08-23 Cancer Therapeutics Crc Pty Limited Selective fak inhibitors
WO2014027199A1 (en) * 2012-08-14 2014-02-20 Cancer Therapeutics Crc Pty Ltd Fak and flt3 inhibitors
WO2020191448A1 (en) * 2019-03-28 2020-10-01 Amplia Therapeutics Limited A salt and crystal form of a fak inhibitor

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
KINOSHITA, K. et al., "Antifibrotic Effects of Focal Adhesion Kinase Inhibitor in Bleomycin-Induced Pulmonary Fibrosis in Mice", AM J RESPIR CELL MOL BIOL, 2013, vol. 49, pages 536-543, DOI: 10.1165/rcmb.2012-02770C *
ZHAO, X. K. et al., "Focal Adhesion Kinase Regulates Fibroblast Migration via Integrin beta-1 and Plays a Central Role in Fibrosis", SCIENTIFIC REPORTS, 2016, vol. 6, article 19276, pages 1-12, DOI: 10.1038/srep19276 *

Also Published As

Publication number Publication date
JP7745571B2 (ja) 2025-09-29
US20230190746A1 (en) 2023-06-22
WO2021237273A1 (en) 2021-12-02
KR20230017843A (ko) 2023-02-06
NZ793855A (en) 2026-02-27
CN115867281A (zh) 2023-03-28
EP4157278A4 (en) 2024-07-03
EP4157278A1 (en) 2023-04-05
AU2021279205A1 (en) 2022-12-08
JP2023527358A (ja) 2023-06-28
CA3177652A1 (en) 2021-12-02

Similar Documents

Publication Publication Date Title
US11975005B2 (en) Treatment of respiratory diseases
ES2666098T3 (es) Combinación de fármacos
AU2018357775B2 (en) New combination of active agents for the treatment of progressive fibrosing interstitial lung diseases (PF-ILD)
EP3551187B1 (en) Nintedanib for use in methods for the treatment of interstitial lung diseases by coadministration with olodaterol
AU2021279205B2 (en) Methods of treating pulmonary fibrosis
JP2012518019A5 (https=)
EP2059259A1 (en) Pharmaceutical compositions for the treatment of fungal infections
US8648100B2 (en) Roflumilast for the treatment of pulmonary hypertension
JP6051315B2 (ja) 乾癬を処置するためのピドチモドの使用
JP2024534156A (ja) Ｎｕｒｒ１アゴニストの、アルドステロンアンタゴニスト、インスリンモジュレーター及びスルホニル尿素のうちの少なくとも１つとの組合せ
AU2002328569B9 (en) Medicinal compositions containing angiotensin II receptor antagonist
EP4175639B1 (en) Masitinib for the treatment of castrate-resistant prostate cancer
RU2809024C2 (ru) Монтелукаст для лечения эрозивного остеоартрита кистей рук
HK40059876A (en) Treatment of respiratory diseases
CN119522109A (zh) 用于钙调磷酸酶抑制剂的间歇性给药的组合物
HK40058742B (zh) 呼吸性疾病的治疗
TW202045184A (zh) 預防或治療肺纖維化的藥物
HK40054679B (en) Montelukast for the treatment of erosive hand osteoarthritis
HK40054679A (en) Montelukast for the treatment of erosive hand osteoarthritis
KR20090119988A (ko) 만성 폐색성 폐질환 치료제
US20040006142A1 (en) Ocular tension depressor
EP0998923A1 (en) Use of 5-HT7 receptor agonists for the treatment or prophylaxis of ischemias
HK1221913B (zh) Par-1拮抗剂用於预防和/或治疗骨盆-会阴功能病状的用途

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: AMPLIA THERAPEUTICS LIMITED

Free format text: FORMER APPLICANT(S): AMPLIA THERAPEUTICS PTY LTD

FGA Letters patent sealed or granted (standard patent)